{
    "eu_accel_assess_g": "True",
    "eu_od_date": "__SCRAPER_NOT_FOUND__",
    "assess_time_days_total": -1,
    "eu_od_pnumber": "__SCRAPER_NOT_FOUND__",
    "active_substance": [
        "brexucabtagene autoleucel",
        "0001-01-01"
    ],
    "assess_time_days_active": 172,
    "eu_od_sponsor": "__SCRAPER_NOT_FOUND__",
    "eu_aut_status": "ACTIVE",
    "eu_od_comp_date": "__SCRAPER_NOT_FOUND__",
    "eu_brand_name_current": [
        {
            "value": "Tecartus",
            "date": "22/12/2022"
        }
    ],
    "assess_time_days_cstop": 90,
    "eu_prime_initial": {
        "value": "True",
        "date": "0001-01-01"
    },
    "ema_corapp": "rune kjeken",
    "eu_indication_initial": {
        "value": "tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton\u2019s tyrosine kinase \n (btk) inhibitor.\n",
        "date": "0001-01-01"
    },
    "ec_decision_time_days": -1,
    "eu_od_con": "__SCRAPER_NOT_FOUND__",
    "eu_od_initial": {
        "value": "adopted",
        "date": "0001-01-01"
    },
    "ema_reexamination": "False",
    "eu_aut_date": "2020-12-14",
    "ema_omar_condition": [
        {
            "eu_od_number": "eu/3/19/2220",
            "eu_od_prevalence": "the prevalence of mantle cell lymphoma (hereinafter referred to as \u201cthe condition\u201d) was estimated to remain below 5 in 10,000 and was concluded to be 0.6 in 10,000 persons in the european union, at the time of the review of the designation criteria; ",
            "eu_od_alt_treatment": "significant_benefit",
            "eu_od_sig_benefit": "__SCRAPER_NOT_FOUND__",
            "ema_report_date": "2020-12-14"
        }
    ],
    "atc_code": "L01X",
    "eu_orphan_con_current": [
        {
            "value": [
                {
                    "pre": "o",
                    "id": "2220",
                    "eu_num": "EU/3/19/2220",
                    "indication": "Treatment of mantle cell lymphoma",
                    "link_date": "2020-12-15"
                },
                {
                    "pre": "o",
                    "id": "2344",
                    "eu_num": "EU/3/20/2344",
                    "indication": "Treatment of acute lymphoblastic leukaemia",
                    "link_date": "2022-09-05"
                }
            ],
            "date": "22/12/2022"
        }
    ],
    "eu_aut_type_initial": {
        "value": "conditional",
        "date": "0001-01-01"
    },
    "chmp_opinion_date": "2020-10-15",
    "eu_referral": "False",
    "eu_procedures_todo": [
        {
            "eu_referral": false,
            "eu_suspension": false
        }
    ],
    "eu_aut_type_current": [
        {
            "value": "conditional",
            "date": "22/12/2022"
        }
    ],
    "ema_rapp": "jan mueller-berghaus",
    "eu_pnumber": "EU/1/20/1492",
    "eu_brand_name_initial": {
        "value": "Tecartus",
        "date": "0001-01-01"
    },
    "eu_suspension": "False",
    "orphan_status": "h",
    "eu_legal_basis": [
        "article 8.3"
    ],
    "ema_number": "EMEA/H/C/005102",
    "aut_url": "404_url_not_found",
    "ema_number_id": "5102",
    "omar_url": "404_url_not_found",
    "smpc_url": "404_url_not_found",
    "ema_number_certainty": "0.9",
    "epar_url": "404_url_not_found",
    "ema_number_check": [
        false,
        "22/12/2022"
    ],
    "odwar_url": "404_url_not_found",
    "eu_mah_current": [
        {
            "value": "Kite Pharma EU B.V.",
            "date": "22/12/2022"
        }
    ],
    "eu_od_number": "__SCRAPER_NOT_FOUND__",
    "eu_atmp": true,
    "eu_mah_initial": {
        "value": "Kite Pharma EU B.V.",
        "date": "0001-01-01"
    },
    "eu_nas": true,
    "ema_od_number": "__SCRAPER_NOT_FOUND__",
    "ema_procedure_start_initial": "2019-12-12",
    "eu_med_type": [
        "small molecule",
        "0001-01-01"
    ]
}